硫氧化还原蛋白1及环氧化酶2在非小细胞肺癌组织的表达及其临床意义  

Expression and clinical implication of thioredoxin 1 and cyclooxygenase 2 in non-small cell lung cancer

作　　者：陈为军[1] 张恩宁[1] 姜文升 李强[3] 杨军[2] 厉吉霞[4] Chen Weijun;Zhang Enning;Jiang Wensheng;Li Qiang;Yang Jun;Li Jixia(Department of Oncology,Yantaishan Hospital of Yantai City,Yantai 264000,China;Department of Cardiothoracic Surgery,Yantaishan Hospital of Yantai City,Yantai 264000,China;Department of Pathology,Yantaishan Hospital of Yantai City,Yantai 264000,China;Department of Clinical Laboratory,Yantaishan Hospital,Yantai 264000,China)

机构地区：[1]烟台市烟台山医院肿瘤科,264000 [2]烟台市烟台山医院心胸外科,264000 [3]烟台市烟台山医院病理科,264000 [4]烟台市烟台山医院检验科,264000

出　　处：《中华实验外科杂志》2022年第8期1454-1456,共3页Chinese Journal of Experimental Surgery

基　　金：烟台市科技计划项目(2019YD038)。

摘　　要：目的检测非小细胞肺癌患者硫氧化还原蛋白1(Trx-1)和环氧化酶2(COX-2)表达并探讨其临床意义。方法选取2019年1月至2021年1月诊治的120例非小细胞肺癌患者为研究对象, 检测组织取自本院胸外科手术切除的肺癌标本(取肺癌组织及距离肿瘤边缘>2 cm的癌旁组织)。链霉菌抗生物素蛋白-过氧化物酶连结法(SP)法检测肺癌组织及癌旁组织Trx-1和COX-2的表达。分析Trx-1和COX-2阳性率与临床病理因素的关系。计量资料比较行t检验;计数资料采用χ2检验。采用Spearman秩相关分析。采用Spearman秩相关分析Trx-1和COX-2表达的相关性。结果肺癌组织中Trx-1和COX-2阳性率显著高于癌旁组织[63.33%(76/120)比20.0%(24/120)、59.17%(71/120)比15.0%(18/120)], 差异有统计学意义(χ^(2)=44.589、48.289, P<0.05)。Trx-1和COX-2阳性率在TNM分期、淋巴结转移及肿瘤分化程度中的差异有统计学意义(χ^(2)=9.234、15.191、22.166、13.752、8.277、11.974, P<0.05), Ⅲ期、有淋巴结转移及肿瘤分化程度低分化患者Trx-1和COX-2阳性率显著高于Ⅰ期+Ⅱ期、无淋巴结转移、高分化及中分化等患者。非小细胞肺癌患者肺癌组织Trx-1和COX-2阳性患者平均疾病进展时间为(20.54±2.63)个月, 3年生存率为37.10%(23/62);其他患者平均疾病进展时间为(23.61±3.18)个月, 3年生存率为63.79%(37/58), Trx-1和COX-2阳性患者患者平均疾病进展时间和3年生存率显著低于未过量表达患者(t或χ^(2)=5.778、8.543, P<0.05)。结论非小细胞肺癌患者中Trx-1和COX-2均呈高表达, 可用于评估非小细胞肺癌患者病情及预后。Objective To detect the expression of thioredoxin 1(Trx-1)and cyclooxygenase-2(COX-2)in patients with non-small cell lung cancer and to explore their clinical significance.Methods Totally,120 pathological specimens of non-small cell lung cancer were chosen for study.Tissues were taken from lung cancer specimens resected by thoracic surgery in our hospital(lung cancer tissue and adjacent tissue more than 2 cm away from the tumor edge).The expression of Trx-1 and COX-2 in 120 cases of non-small cell lung cancer and adjacent lung tissues was measured.Measurement data were compared by t test.Enumeration data were compared by χ^(2) test.Spearman rank correlation analysis was used.Results The positive rate of Trx-1 and COX-2 in lung cancer tissues was significantly higher than that in adjacent tissues[63.33%(76/120)vs.20.0%(24/120);59.17%(71/120)vs.15.0%(18/120),respectively],and the difference was statistically significant(χ^(2)=44.589,48.289,P<0.05).There were significant differences in the positive rate of Trx-1 and COX-2 in TNM staging,lymph node metastasis and tumor differentiation(χ^(2)=9.234,15.191,22.166,13.752,8.277,11.974,P<0.05).The average disease progression time in non-small cell lung cancer patients positive for Trx-1 and COX-2 was(20.54±2.63)months,and the 3-year survival rate was 37.10%(23/62);the average disease progression time of other patients was(23.61±3.18)months,the 3-year survival rate was 63.79%(37/58),and the mean disease progression time and 3-year survival rate in patients positive for Trx-1 and COX-2 were significantly reduced as compared with those in patients without overexpression(t or χ^(2)=5.778,8.543,P<0.05).Conclusion The Trx-1 and COX-2 are highly expressed in patients with non-small cell lung cancer,which can be used to evaluate the condition and prognosis of patients with non-small cell lung cancer.

关 键 词：非小细胞肺癌 硫氧化还原蛋白1 环氧化酶2 

分 类 号：R734.2[医药卫生—肿瘤]